Nutex Health Inc
$ 162.07
6.67%
07 Aug - close price
- Market Cap 1,109,851,000 USD
- Current Price $ 162.07
- High / Low $ 173.00 / 152.38
- Stock P/E 6.28
- Book Value 49.81
- EPS 25.80
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.29 %
- ROE 0.54 %
- 52 Week High 204.00
- 52 Week Low 77.21
About
Nutex Health, Inc. is a technology-based healthcare services company. The company is headquartered in Houston, Texas.
Analyst Target Price
$246.40
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-04-30 | 2026-03-05 | 2025-10-22 | 2025-06-30 | 2025-05-13 | 2025-03-31 | 2024-11-08 | 2024-08-08 | 2024-05-08 | 2024-03-28 | 2023-11-09 |
| Reported EPS | 9.58 | 5.74 | 1.62 | 7.76 | 5.2262 | 1.78 | 11.12 | -0.32 | -0.15 | -0.06 | -7.5 | -1.25 |
| Estimated EPS | 5.26 | 5.56 | 5.5567 | 1.95 | -5.43 | 3.91 | -0.1233 | 0.28 | -0.29 | None | -0.005 | -1.5 |
| Surprise | 4.32 | 0.18 | -3.9367 | 5.81 | 10.6562 | -2.13 | 11.2433 | -0.6 | 0.14 | 0 | -7.495 | 0.25 |
| Surprise Percentage | 82.1293% | 3.2374% | -70.846% | 297.9487% | 196.2468% | -54.4757% | 9118.6537% | -214.2857% | 48.2759% | None% | -149900% | 16.6667% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NUTX
2026-08-07 18:11:43
Nutex Health (NUTX) reported a significant profit beat in Q2 2026, with adjusted earnings of $9.38 per share against an estimate of $4.88, despite revenue slightly missing forecasts at $210.75 million. The company's shares rose over 10% as investors reacted positively to stronger margins, reduced arbitration costs due to regulatory changes and a renegotiated HaloMD contract, and improved cash generation. Nutex reaffirmed its guidance for opening three to five hospitals per year and outlined plans for expansion in 2027 and beyond, including more company-owned developments.
2026-08-07 16:11:08
Nutex Health (NASDAQ: NUTX) reported a significant improvement in Q2 profitability and adjusted EBITDA, despite a 13.6% decline in revenue. This was primarily driven by reduced arbitration-related costs, including a lower CMS independent dispute resolution fee and revised terms with HaloMD. The company also saw positive patient volume growth and plans for further hospital expansion in Arkansas, Texas, and Florida.
2026-08-06 22:11:09
Nutex Health (NASDAQ: NUTX) reported Q2 2026 revenue of $210.8 million, a 13.6% decrease, but saw diluted EPS improve significantly to $9.38 from a previous loss. This profit increase was driven by a substantial reduction in arbitration-related costs and lower stock-based compensation, which offset the revenue decline. The company's operating cash flow also rose, and while patient visits increased, the timing and collection of IDR awards remain crucial for reported revenue.
2026-08-06 22:11:08
Nutex Health has reported its financial results for the second quarter of 2026. The press release details the company's performance, providing key financial metrics and highlights from the quarter. Further specifics would require access to the full document.
2026-08-06 18:10:32
Nutex Health Inc. is reporting its second-quarter earnings, which will provide insight into the success of its "capital-light" expansion strategy. Analysts expect earnings of $4.95 per share on $215.03 million in revenue, a sequential decrease from the previous quarter. The report will focus on the company's execution velocity of new facility openings and its out-of-network payment strategy, alongside its ability to maintain strong unit economics and margins as it grows.
2026-08-05 18:11:43
Empowered Funds LLC has acquired a new stake of 32,451 shares in Nutex Health Inc. (NASDAQ:NUTX), valued at approximately $3.08 million, representing 0.47% of the company. Institutional investors collectively own 5.32% of NUTX, and analysts have a "Moderate Buy" consensus rating with an average price target of $243.33. The stock opened at $157.80, with a market capitalization of $1.09 billion.
